Nanoparticles Mimicking Viral Cell Recognition Strategies Are Superior Transporters into Mesangial Cells.
mesangial cells
multivalent nanoparticles
renal targeting
stepwise cell recognition
virus‐mimetic
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
11
11
2019
revised:
12
03
2020
accepted:
17
03
2020
entrez:
16
6
2020
pubmed:
17
6
2020
medline:
17
6
2020
Statut:
epublish
Résumé
Poor drug availability in the tissue of interest is a frequent cause of therapy failure. While nanotechnology has developed a plethora of nanocarriers for drug transport, their ability to unequivocally identify cells of interest remains moderate. Viruses are the ideal nanosized carriers as they are able to address their embedded nucleic acids with high specificity to their host cells. Here, it is reported that particles endowed with a virus-like ability to identify cells by three consecutive checks have a superior ability to recognize mesangial cells (MCs) in vivo compared to conventional nanoparticles. Mimicking the initial viral attachment followed by a stepwise target cell recognition process leads to a 5- to 15-fold higher accumulation in the kidney mesangium and extensive cell uptake compared to particles lacking one or both of the viral traits. These results highlight the relevance that the viral cell identification process has on specificity and its application on the targeting strategies of nanomaterials. More so, these findings pave the way for transporting drugs into the mesangium, a tissue that is pivotal in the development of diabetic nephropathy and for which currently no efficient pharmacotherapy exists.
Identifiants
pubmed: 32537398
doi: 10.1002/advs.201903204
pii: ADVS1704
pmc: PMC7284201
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1903204Informations de copyright
© 2020 The Authors. Advanced Science published by Wiley‐VCH Verlag GmbH & Co. KGaA.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Soft Matter. 2019 Jan 28;15(4):709-720
pubmed: 30624437
Cell. 1993 Apr 23;73(2):309-19
pubmed: 8477447
Small. 2010 Jan;6(1):12-21
pubmed: 19844908
Kidney Int. 1976 May;9(5):395-406
pubmed: 181634
Trends Biotechnol. 2007 Jun;25(6):247-9
pubmed: 17433847
Arthritis Rheum. 2008 Dec;58(12):3884-91
pubmed: 19035491
J Drug Target. 2015;23(7-8):681-9
pubmed: 25950599
Angew Chem Int Ed Engl. 1998 Nov 2;37(20):2754-2794
pubmed: 29711117
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9831-9836
pubmed: 31036631
J Biomed Mater Res A. 2008 May;85(2):539-46
pubmed: 17729259
Biomaterials. 2014 Mar;35(9):2568-79
pubmed: 24411677
Hypertension. 2004 Sep;44(3):352-9
pubmed: 15262908
Nucleic Acid Ther. 2015 Apr;25(2):53-64
pubmed: 25734248
J Hypertens. 1993 Feb;11(2):155-62
pubmed: 8385175
FEBS Lett. 1990 Jul 30;268(1):235-7
pubmed: 2384160
Hum Gene Ther. 2003 Nov 1;14(16):1565-77
pubmed: 14577918
J Control Release. 2014 Nov 28;194:20-7
pubmed: 25128717
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10667-72
pubmed: 20498042
Am J Physiol Renal Physiol. 2004 Jun;286(6):F1039-45
pubmed: 14722017
Adv Drug Deliv Rev. 2010 Nov 30;62(14):1337-43
pubmed: 20828589
ACS Appl Mater Interfaces. 2015 May 20;7(19):10374-85
pubmed: 25909493
Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6656-61
pubmed: 21464325
Can J Physiol Pharmacol. 2003 Mar;81(3):274-87
pubmed: 12733826
Viruses. 2015 Jun 02;7(6):2794-815
pubmed: 26043381
J Virol. 2006 Dec;80(24):11960-7
pubmed: 17005658
Antimicrob Agents Chemother. 1982 May;21(5):830-5
pubmed: 6285815
J Clin Invest. 2003 Mar;111(5):707-16
pubmed: 12618525
Macromolecules. 2011 Sep 27;44(18):7132-7140
pubmed: 22287809
Chem Biol. 2007 Jan;14(1):107-15
pubmed: 17254956
Colloids Surf B Biointerfaces. 2000 Oct 1;18(3-4):301-313
pubmed: 10915952
Science. 2004 Apr 9;304(5668):237-42
pubmed: 15073366
J Biol Chem. 1985 Mar 25;260(6):3440-50
pubmed: 3838314
Cell. 2006 Feb 24;124(4):729-40
pubmed: 16497584
J Control Release. 2015 Dec 28;220(Pt A):265-274
pubmed: 26494258
Mol Endocrinol. 1997 Aug;11(9):1266-77
pubmed: 9259318
Nat Mater. 2016 Nov;15(11):1212-1221
pubmed: 27525571
Nat Biotechnol. 2005 Nov;23(11):1418-23
pubmed: 16244656
Pharm Res. 2007 May;24(5):946-54
pubmed: 17372685
Phys Rev Lett. 2017 Feb 10;118(6):068001
pubmed: 28234514
J Am Soc Nephrol. 2009 Jun;20(6):1179-87
pubmed: 19470685
Kidney Int. 2004 Oct;66(4):1365-75
pubmed: 15458429
Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4581-91
pubmed: 21712414
J Gene Med. 2002 Sep-Oct;4(5):527-35
pubmed: 12221646
J Cell Biol. 2010 Dec 27;191(7):1381-93
pubmed: 21187331
J Pharm Sci. 1990 Sep;79(9):763-7
pubmed: 2273454
ACS Appl Mater Interfaces. 2019 Jan 9;11(1):1311-1320
pubmed: 30521749
Biochem J. 2004 Oct 1;383(Pt 1):45-51
pubmed: 15283675
J Pharmacol Exp Ther. 2011 May;337(2):411-22
pubmed: 21349934
Am J Physiol Renal Physiol. 2009 May;296(5):F947-56
pubmed: 19129259
Pharmacol Rev. 2000 Sep;52(3):415-72
pubmed: 10977869
Nephron. 2001 Oct;89(2):194-200
pubmed: 11549902
Nat Rev Nephrol. 2014 Dec;10(12):700-11
pubmed: 25311535
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Cell Biol. 2011 Dec 26;195(7):1071-82
pubmed: 22123832
Adv Chronic Kidney Dis. 2013 Nov;20(6):500-7
pubmed: 24206602
J Am Soc Nephrol. 2005 Nov;16(11):3295-305
pubmed: 16176998
Nat Clin Pract Endocrinol Metab. 2008 Aug;4(8):444-52
pubmed: 18607402
Adv Sci (Weinh). 2020 Apr 22;7(11):1903204
pubmed: 32537398
Cell. 2006 Oct 6;127(1):113-24
pubmed: 17018281